{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:56:52Z","timestamp":1783951012707,"version":"3.55.0"},"reference-count":28,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100017639","name":"Entasis Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017639","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,2,21]]},"abstract":"<jats:p>\n            Durlobactam (DUR; ETX2514) is a novel \u03b2-lactamase inhibitor with broad-spectrum activity against Ambler class A, C, and D \u03b2-lactamases. Durlobactam restores the\n            <jats:italic>in vitro<\/jats:italic>\n            activity of sulbactam (SUL) against members of the\n            <jats:named-content content-type=\"genus-species\">Acinetobacter baumannii<\/jats:named-content>\n            -\n            <jats:named-content content-type=\"genus-species\">A. calcoaceticus<\/jats:named-content>\n            complex (ABC). Sulbactam (SUL)-durlobactam (SUL-DUR) is under development for the treatment of ABC infections.\n          <\/jats:p>","DOI":"10.1128\/aac.01506-19","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T12:59:03Z","timestamp":1576501143000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":56,"title":["Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis"],"prefix":"10.1128","volume":"64","author":[{"given":"Olexiy","family":"Sagan","sequence":"first","affiliation":[{"name":"Regional Clinical Hospital of Zaporizhzhia, Zaporizhzhia, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruslan","family":"Yakubsevitch","sequence":"additional","affiliation":[{"name":"Grodno Regional Clinical Hospital, Hrodna, Belarus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krassimir","family":"Yanev","sequence":"additional","affiliation":[{"name":"Clinic of Urology, Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Fomkin","sequence":"additional","affiliation":[{"name":"Saratov State Medical University, Saratov, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Stone","sequence":"additional","affiliation":[{"name":"Spero Therapeutics, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Hines","sequence":"additional","affiliation":[{"name":"Entasis Therapeutics, Inc., Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"Entasis Therapeutics, Inc., Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alita","family":"Miller","sequence":"additional","affiliation":[{"name":"Entasis Therapeutics, Inc., Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Isaacs","sequence":"additional","affiliation":[{"name":"Entasis Therapeutics, Inc., Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subasree","family":"Srinivasan","sequence":"additional","affiliation":[{"name":"Entasis Therapeutics, Inc., Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"European Center for Disease Prevention and Control. 2016. Summary of the latest data on antibiotic resistance in the European Union. http:\/\/ecdc.europa.eu\/en\/eaad\/Documents\/antibiotics-EARS-Net-summary-2016.pdf. Accessed 5 June 2018."},{"key":"e_1_3_2_3_2","volume-title":"Antibiotic resistance threats in the United States","author":"U.S. Department of Health and Human Services, Centers for Disease Control and Prevention","year":"2013","unstructured":"U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States. Centers for Disease Control and Prevention, Atlanta, GA. https:\/\/www.cdc.gov\/drugresistance\/pdf\/ar-threats-2013-508.pdf."},{"key":"e_1_3_2_4_2","volume-title":"Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. 2017. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. Report WHO\/EMP\/IAU\/2017.12. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx176"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/668770"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2404.171461"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy293"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1599225"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/MCC.0000000000000337"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12363"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00058-16"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-016-1392-4"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000000933"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000001029"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.2477"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00159-19"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/nmicrobiol.2017.104"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.7b00113"},{"key":"e_1_3_2_20_2","volume-title":"Abstr ASM Microbe","author":"McLeod SM","year":"2017","unstructured":"McLeod SM, Roth B, Flamm R, Huband M, Mueller J, Tommasi R, Perros M, Miller A. 2017. The antibacterial activity of sulbactam and the novel beta-lactamase inhibitor ETX2514 combined with imipenem or meropenem against recent clinical isolates of Acinetobacter baumannii and Pseudomonas aeruginosa, abstr Friday-82. Abstr ASM Microbe. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01576-17"},{"key":"e_1_3_2_22_2","unstructured":"McLeod SM Moussa S Hackel M Tommasi R Miller A. 2019. The novel beta-lactamase inhibitor ETX2514 effectively restores sulbactam activity against recent global Acinetobacter baumannii-calcoaceticus complex clinical isolates abstr P1185. Abstr 29th Eur Congr Clin Microbiol Infect Dis."},{"key":"e_1_3_2_23_2","unstructured":"Seifert H Stefanik D Muller C Kresken M Higgins PG Miller A. 2019. The susceptibility of global isolates of Acinetobacter baumannii to ETX2514SUL and comparators abstr P1186. Abstr 29th Eur Congr Clin Microbiol Infect Dis."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx163.1366"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00794-19"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01089-18"},{"key":"e_1_3_2_27_2","unstructured":"Onufrak NJ Rubino CM Ambrose PG Isaacs R Srinivasan S O\u2019Donnell J. 2019. Population pharmacokinetic and pharmacokinetic-pharmacodynamic target attainment analyses of ETX2514SUL to support dosing regimens in patients with varying renal function poster P1953. Abstr 29th Eur Congr Clin Microbiol Infect Dis."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2019.03.003"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30099-9"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01506-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01506-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:45:31Z","timestamp":1645479931000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01506-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,21]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,2,21]]}},"alternative-id":["10.1128\/AAC.01506-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.01506-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,21]]},"assertion":[{"value":"2019-07-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01506-19"}}